Biotechnology
BT 2120 | 2013
BIOMARKERS MARKET ([Discovery Technologies -Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [Drug Development, Personalized Medicine], Diseases [Oncology, Cardiology, Neurology) – Global Trends & Forecasts (2013 – 2018)
Report Description
Table of Contents List of Tables Sample Tables Related Reports About MarketsandMarkets
MarketsandMarkets North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252, U.S. Tel. No.: 1-888-600-6441 Email: sales@marketsandmarkets.com Website: www.marketsandmarkets.com
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Report Description Key Take-Aways •
•
Definition, measurement, and forecast of the global biomarkers market on the basis of its discovery technologies, services, applications, and disease indications
stakeholders and details of a competitive landscape for market leaders
Detailed information regarding the major factors influencing the growth of the market (drivers, restraints, and industry specific challenges, among others)
•
Strategic analysis of micro-markets with respect to individual growth trends, future prospects, and contribution to the total market
•
Analyzing the opportunities in the market for
•
Forecasting revenue of market segments with respect to four main geographies, namely, North America, Europe, Asia-Pacific, and Rest of the World
•
Strategic profiling of key players and comprehensively analyzing their market shares and core competencies
•
Tracking and analyzing competitive developments such as, joint ventures, mergers and acquisitions, new product developments, and research and development in the biomarkers market
Report Description A number of concerns over treatment efficacy, cost, and drug safety have stimulated a need for personalized medicine. This has forced market players to make considerable improvements in the predictability of clinical and pre-clinical researches, to reduce the time and cost involved in the drug development process. Biomarkers play a significant role in the drug development process, as they reduce the overall time and cost involved in drug development and its validation. The market is thus perceived as an emerging and lucrative segment which is opening up new opportunities for industry players.
Technological advancements in proteomics and genomics are the major factors contributing to the growth of the omics technology segment. Biomarkers Market, by services: The biomarker validation and testing segment accounts for the largest share of the biomarker services market; it is estimated to grow at a CAGR of xx% from 2013 to 2018, to reach ~$xx billion by 2018. Increasing demand for the development of novel therapeutic drugs and the increasing number of contract research organizations are the major drivers for the biomarker validation and testing services market.
Increasing demand of drug discovery and development (due to rise in the prevalence of chronic diseases), technological advancements in biomarker discovery technologies, government and private sector funds for biomarker research, and FDA support for integration of biomarkers in the drug development process are the key factors propelling the growth of the biomarkers market. The biomarkers market is worth~ $xx billion in 2013 and is estimated to grow at a CAGR of xx% from 2013 to 2018. However, factors such as high capital investment and low benefit-cost ratio, costly and time consuming biomarker validation process, and cumbersome sample collection and storage procedures are major restraints for this market.
Biomarkers market, by applications: Drug discovery and development is the largest segment of the biomarker applications market with a share of xx%. It is expected to grow at a CAGR of xx% from 2013 to 2018, to reach $xx billion by 2018. The growth in this market is primarily driven by the potential of biomarkers to reduce the overall cost and time involved in the development and approval of a specific drug. Biomarkers market, by disease indications: Oncology biomarkers hold the largest share of xx% of the biomarker disease indication market; it is estimated to reach $xx billion by 2018. The growth of the oncology biomarkers market is attributed to the high demand of tumor markers, to reduce cancer mortality rates by facilitating the diagnosis of cancers at early stages.
Biomarkers market, by discovery technology: The omics technologies account for the largest share of the biomarker discovery technology market; it is poised to grow at a CAGR of xx% from 2013 to 2018, to reach ~$xx billion by 2018.
www.marketsandmarkets.com sales@marketsandmarkets.com
2
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Report Description North America holds the largest share—~xx%—of the global biomarkers market in 2013, followed by Europe (~xx% share). However, Asia-Pacific and RoW (Rest of the World) regions represent the fastest growing markets. This is due to the growing number of contract research organizations and pharmaceuticals and diagnostics companies, increasing number of clinical research projects in the field of biomarkers, and government funding to research institutes and universities in these regions. However, low adoption rate of advanced technologies, budget
constraints for research institutes and universities, and regulatory hurdles are the major challenges faced by the AsiaPacific biomarkers market. The key players in the biomarkers market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Epigenomics AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), and Merck & Co. (U.S.)
Markets Covered This research report categorizes the market for biomarkers into the following segments: Global Biomarkers Market, by Discovery Technologies
•
Assay Development
•
Biomarker Validation and Testing
Global Biomarkers Market, By Applications
•
Imaging Technologies
•
Drug Discovery and Development
•
Omics Technologies
•
Personalized Medicine
§ Proteomics
•
Molecular Diagnostics
§ Genomics
•
Other Applications
§ Transcriptomics
•
Global Biomarkers Market, by Disease Indications
§ Metabolomics
•
Oncology
Bioinformatics
•
Cardiology
•
Neurology
•
Others
Global Biomarkers Market, by Services •
Sample Preparation
Stakeholders •
Pharmaceutical and biotechnology companies
•
Diagnostic companies and biomarker service providers
•
Biopharmaceutical and biomarker companies
•
Research institutes
•
Contract research manufacturing companies
•
Market research and consulting firms
www.marketsandmarkets.com sales@marketsandmarkets.com
3
BT 2120 2013
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
Report Description Research Methodology Market Size Global Biomarkers Market • A top-down approach was used to calculate the global biomarkers market and its subsegments • A geographic split-up was given post calculating the market for each segment • Key data points were collected from public and paid secondary databases and successively validated from primary sources
Key Data Points from Secondary Sources Parameter
Data Point
Market Revenue
Company financials, magazines, journals, press releases, paid databases, and MnM data repository
Market Revenue of Companies
Annual reports, company websites, public databases and MnM data repository, paid databases
Qualitative Information (Market Dynamics, Market Trends)
Annual reports, company websites, press releases and MnM data repository, paid databases
Key Data Points from Primary Sources Parameter
Data Point
The global biomarkers market
The global market size for the year 2013 and CAGR for the forecast period (2013-2018)
The global biomarkers market, by geography – North America, Europe, Asia-Pacific, and RoW
Geographic split for the overall market and sub-segments in 2013 and CAGR of each region in the forecast period (2013 - 2018)
Biomarkers market, by discovery technologies
Market split for discovery technologies and their sub-segments - omics, imaging, and bioinformatics
Biomarker services market
Market split for biomarker services - sample preparation, assay development, and biomarker validation and testing
www.marketsandmarkets.com sales@marketsandmarkets.com
4
BT 2120 2013
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
Report Description Parameter
Data Point
Biomarkers market, by applications
Market split for biomarker applications - drug development, personalized medicine, molecular diagnostics, and others
Biomarkers market, by disease indications
Market split for biomarker applications for various disease indications – oncology, cardiology, neurology, and others
Assumptions Parameters Geographic split
Assumptions Global biomarker market and CAGR for the next five years is calculated and triangulated from primary sources. The overall market was then represented by three types, namely, Market Size discovery technologies, applications, and disease indications. Overall market for each sub segment has also been triangulated from various secondary and primary sources. • Biomarker Discovery Technologies Market: Overall biomarkers market was split up based on technologies that are used to discover these biomarkers • Biomarker Application Market: Overall biomarkers market was split up based on the three main applications of biomarkers • Biomarker Disease Indications Market: Overall biomarkers market was split up based on three main disease indications, namely, oncology, cardiology, and neurology, for which discovery technologies (such as imaging, omics, and bioinformatics) and biomarker applications (such as drug development, personalized medicine, and molecular diagnostics) were utilized insync, to identify novel biomarkers.
Biomarker Market, by Discovery Technologies
Base year for calculation is 2012. A percentage split of XX% omics, XX% imaging and XX% bioinformatics has been assumed, which has then been confirmed by primary sources.
Biomarker Market, by Applications
Base year for calculation is 2012. A percentage split of XX% drug discovery and development, XX% personalized medicine, XX% molecular diagnostics, and XX% others has been assumed, which has then been confirmed by primary sources.
Biomarker Market, by Disease Indication
Base year for calculation is 2012. A percentage split of XX% oncology, XX% cardiology, XX% neurology, and XX% others has been assumed, which has then been confirmed by primary sources.
Biomarker Services Market
Base year for calculation is 2012. A percentage split of XX% for sample preparation, XX% assay development, and XX% validation and testing has been assumed, which has then been confirmed by primary sources.
www.marketsandmarkets.com sales@marketsandmarkets.com
5
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Table of Contents Chapter Headings .....................................................................................................................Page No 1.
Introduction .......................................................................................................................................27 1.1
Key Take-Aways....................................................................................................................................................27
1.2
Report Description ...............................................................................................................................................27
1.3
Markets Covered...................................................................................................................................................29
1.4
Stakeholders .........................................................................................................................................................30
1.5
Research Methodology ........................................................................................................................................31
1.5.1
Market size ......................................................................................................................................................31
1.5.2
Key data points from secondary sources ........................................................................................................31
1.5.3
Key data points from primary sources.............................................................................................................31
1.5.4
Assumptions....................................................................................................................................................32
2.
Executive Summary ..........................................................................................................................34
3.
Market Overview ................................................................................................................................38 3.1
Introduction...........................................................................................................................................................39
3.2
Market Segmentation ...........................................................................................................................................42
3.3
Market Dynamics ..................................................................................................................................................44
3.3.1
Drivers .............................................................................................................................................................45
3.3.1.1 High demand from the indications of various diseases boosts the growth of the biomarkers market globally .........................................................................................................................................45 3.3.1.2 Strategic collaborations lead to increasing research activities on biomarkers .........................................45 3.3.1.3 Advancements in discovery technologies have accelerated the research studies on biomarkers...........46 3.3.1.4 Unmet market needs attracting investment and funds for biomarker research and development ...........46 3.3.1.5 FDA support for biomarker development .................................................................................................47 3.3.1.6 Increasing utility of biomarkers in patient stratification and drug development process ..........................47 3.3.2
Restraints ........................................................................................................................................................48
3.3.2.1 High capital investment & low benefit-cost ratio hinders the growth of biomarkers .................................48 3.3.2.2 Biomarkers are not a profitable market for small organizations ...............................................................48 3.3.2.3 Sample collection & storage.....................................................................................................................49 3.3.2.4 Cumbersome biomarker validation process.............................................................................................49 3.3.3
Opportunities ...................................................................................................................................................49
www.marketsandmarkets.com sales@marketsandmarkets.com
6
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Table of Contents Chapter Headings .....................................................................................................................Page No 3.3.3.1 Personalized medicine .............................................................................................................................49 3.3.3.2 Companion diagnostics............................................................................................................................50 3.3.4
Challenges ......................................................................................................................................................51
3.3.4.1 Variability ..................................................................................................................................................51 3.3.4.2 Ethical considerations & acceptability ......................................................................................................52
4.
Global Biomarkers Market, by Discovery Technologies ...............................................................53 4.1
Introduction...........................................................................................................................................................54
4.2
Omics Technologies for Biomarker Discovery ..................................................................................................58
4.2.1
Proteomics ......................................................................................................................................................61
4.2.1.1 Mass spectrometry...................................................................................................................................62 4.2.1.1.1
Maldi mass spectrometry .............................................................................................................64
4.2.1.1.2
Imaging mass spectrometry .........................................................................................................64
4.2.1.2 2D gel electrophoresis .............................................................................................................................64 4.2.1.3 Protein microarray technology .................................................................................................................65 4.2.1.4 Antibody array technology........................................................................................................................66 4.2.1.5 Peptide array technology .........................................................................................................................66 4.2.2
Genomics ........................................................................................................................................................67
4.2.2.1 Whole genome sequencing......................................................................................................................68 4.2.2.2 Genotyping...............................................................................................................................................69 4.2.2.3 Epigenetics...............................................................................................................................................69 4.2.3
Transcriptomics ...............................................................................................................................................70
4.2.3.1 Microarrays ..............................................................................................................................................72 4.2.3.2 Gene expression profiling ........................................................................................................................73 4.2.4
Metabolomics ..................................................................................................................................................73
4.2.4.1 Capillary electrophoresis..........................................................................................................................75 4.2.4.2 Mass spectrometry based kits..................................................................................................................75 4.2.4.3 Nuclear Magnetic Resonance (NMR) ......................................................................................................75 4.3
Imaging Technologies for Biomarker Discovery ...............................................................................................76
4.3.1
Magnetic Resonance Imaging (MRI)...............................................................................................................79
4.3.2
Positron Emission Tomography (PET) ............................................................................................................81
4.3.3
Computed Tomography (CT)...........................................................................................................................82
4.3.4
Single-Photon Emission Computed Tomography (SPECT) ............................................................................83
www.marketsandmarkets.com sales@marketsandmarkets.com
7
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Table of Contents Chapter Headings .....................................................................................................................Page No 4.3.5 4.4
5.
Cluster analysis ...............................................................................................................................................89
4.4.2
Statistical analysis ...........................................................................................................................................91
4.4.3
Data mining .....................................................................................................................................................93
4.4.4
Cell signal pathways........................................................................................................................................95
4.4.5
Protein interaction maps..................................................................................................................................96
4.4.6
Computer aided design ...................................................................................................................................97
Global Biomarker Services Market ..................................................................................................99 Clinical Services .................................................................................................................................................100
5.1.1
Sample preparation .......................................................................................................................................103
5.1.2
Assay development .......................................................................................................................................105
5.1.3
Biomarker validation and testing ...................................................................................................................106
5.2
7.
Bioinformatics.......................................................................................................................................................86
4.4.1
5.1
6.
Ultrasound .......................................................................................................................................................85
Importance of Bioinformatics in Providing Biomarker Services ...................................................................109
Global Biomarkers Market, by Applications .................................................................................110 6.1
Introduction .........................................................................................................................................................111
6.2
Drug Discovery & Development ........................................................................................................................114
6.3
Molecular Diagnostics........................................................................................................................................116
6.4
Personalized Medicine .......................................................................................................................................117
6.5
Other Applications..............................................................................................................................................121
Global Biomarkers Market, by Disease Indication .......................................................................122 7.1
Introduction.........................................................................................................................................................123
7.1.1
Oncology biomarkers market ........................................................................................................................125
7.1.1.1 Breast cancer .........................................................................................................................................128 7.1.1.2 Lung cancer ...........................................................................................................................................129 7.1.1.3 Prostate cancer ......................................................................................................................................129 7.1.1.4 Colorectal cancer ...................................................................................................................................130
www.marketsandmarkets.com sales@marketsandmarkets.com
8
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Table of Contents Chapter Headings .....................................................................................................................Page No 7.1.1.5 Cervical cancer ......................................................................................................................................130 7.1.1.6 Other cancers.........................................................................................................................................131 7.1.2
Cardiology biomarkers market ......................................................................................................................131
7.1.2.1 Acute coronary syndrome ......................................................................................................................132 7.1.2.2 Coronary artery disease.........................................................................................................................133 7.1.2.3 Stroke.....................................................................................................................................................133 7.1.2.4 Other cardiac diseases ..........................................................................................................................134 7.1.3
Neurology biomarkers market .......................................................................................................................136
7.1.3.1 Alzheimer’s disease ...............................................................................................................................137 7.1.3.2 Parkinson’s disease ...............................................................................................................................137 7.1.3.3 Multiple sclerosis....................................................................................................................................138 7.1.3.4 Schizophrenia ........................................................................................................................................138 7.1.3.5 Other neurological diseases...................................................................................................................139 7.1.4
8.
9.
Other indication biomarkers market ..............................................................................................................139
Geographic Analysis.......................................................................................................................141 8.1
Introduction.........................................................................................................................................................142
8.2
North America .....................................................................................................................................................144
8.3
Europe .................................................................................................................................................................152
8.4
Asia-Pacific .........................................................................................................................................................161
8.5
RoW (Rest of the World) ....................................................................................................................................169
Competitive Landscape ..................................................................................................................175 9.1
Introduction.........................................................................................................................................................175
9.2
Agreements, Partnerships, Collaborations, and Joint Ventures....................................................................176
9.3
New Product Launch ..........................................................................................................................................195
9.4
Mergers and Acquisitions..................................................................................................................................200
9.5
Other Developments...........................................................................................................................................204
www.marketsandmarkets.com sales@marketsandmarkets.com
9
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Table of Contents Chapter Headings .....................................................................................................................Page No 10.
Company Profiles ............................................................................................................................210
(Overview, Financials, Products & Services, Strategy, and Developments)* 10.1
ABBOTT LABORATORIES .................................................................................................................................210
10.2
AFFYMETRIX, INC...............................................................................................................................................216
10.3
AGILENT TECHNOLOGIES, INC. .......................................................................................................................222
10.4
BIO-RAD LABORATORIES, INC.........................................................................................................................228
10.5
EISAI CO. LTD. ....................................................................................................................................................234
10.6
ELI LILLY AND COMPANY..................................................................................................................................242
10.7
EPIGENOMICS AG ..............................................................................................................................................247
10.8
GE HEALTHCARE ...............................................................................................................................................252
10.9
GENOMIC HEALTH, INC. ....................................................................................................................................258
10.10 GLAXOSMITHKLINE PLC (GSK)........................................................................................................................261 10.11 HOLOGIC, INC.....................................................................................................................................................266 10.12 IMMUNOMEDICS, INC.........................................................................................................................................271 10.13 JOHNSON & JOHNSON......................................................................................................................................275 10.14 MERCK & CO.......................................................................................................................................................282 10.15 MYRIAD GENETICS, INC. ...................................................................................................................................287 10.16 QIAGEN NV..........................................................................................................................................................295 10.17 ROCHE DIAGNOSTICS LIMITED .......................................................................................................................302 10.18 SIEMENS HEALTHCARE ....................................................................................................................................310 10.19 THERMO FISHER SCIENTIFIC, INC...................................................................................................................318 10.20 TRANS-HIT BIOMARKERS, INC.........................................................................................................................324 *Details on Overview, Financials, Product & Services, Strategy, and Developments might not be captured in case of unlisted companies.
www.marketsandmarkets.com sales@marketsandmarkets.com
10
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
List of Tables Table Titles
..........................................................................................................................Page No
1
Global Biomarker Market, by Discovery Technology, 2011 - 2018 ($Million)................................................................56
2
Global Biomarker Discovery Technology Market, by Geography, 2011 - 2018 ($Million) .............................................57
3
Global Biomarker Discovery Market, by Omics Technology, 2011 - 2018 ($Million).....................................................60
4
Global Biomarker Omics Technologies Market, by Geography, 2011 - 2018 ($Million)................................................61
5
Biomarker Proteomics Market, by Geography, 2011 - 2018 ($Million) .........................................................................62
6
Biomarker Genomics Market, by Geography, 2011 - 2018 ($Million) ...........................................................................68
7
Biomarker Transcriptomics Market, by Geography, 2011 - 2018 ($Million) ..................................................................72
8
Biomarker Metabolomics Market, by Geography, 2011 - 2018 ($Million) .....................................................................74
9
Global Biomarker Discovery Market, by Imaging Technology, 2011 - 2018 ($Million) ..................................................78
10
Global Biomarker Imaging Technologies Market, by Geography, 2011 - 2018 ($Million) .............................................79
11
MRI Biomarker Market, by Geography, 2011 - 2018 ($Million).....................................................................................80
12
PET Biomarker Market, by Geography, 2011 - 2018 ($Million) ....................................................................................82
13
Computed Tomography Biomarker Market, by Geography, 2011 - 2018 ($Million) ......................................................83
14
SPECT Biomarker Market, by Geography, 2011 - 2018 ($Million) ...............................................................................84
15
Ultrasound Biomarker Market, by Geography, 2011 - 2018 ($Million) ..........................................................................86
16
Global Biomarkers Market, by Bioinformatics Applications, 2011 - 2018 ($Million) ......................................................88
17
Biomarker Bioinformatics Market, by Geography, 2011 - 2018 ($Million).....................................................................89
18
Biomarker Cluster Analysis Market, by Geography, 2011 - 2018 ($Million)..................................................................91
19
Biomarker Statistical Analysis Market, by Geography, 2011 - 2018 ($Million)..............................................................92
20
Biomarker Data Mining Market, by Geography, 2011 - 2018 ($Million) ........................................................................94
21
Biomarker Cell Signal Pathways Market, by Geography, 2011 - 2018 ($Million)..........................................................96
22
Biomarker Protein Interaction Maps Market, by Geography, 2011 - 2018 ($Million) ....................................................97
23
Biomarker Computer Aided Design Market, by Geography, 2011 - 2018 ($Million) .....................................................98
24
Global Biomarker Services Market, by Type, 2011 - 2018 ($Million) ..........................................................................102
25
Global Biomarker Services Market, by Geography, 2011 - 2018 ($Million) ................................................................103
26
Global Biomarker Sample Preparation Services Market, by Geography, 2011 - 2018 ($Million) ...............................104
27
Global Biomarker Assay Development Services Market, by Geography, 2011 - 2018 ($Million) ...............................106
28
Global Biomarker Validation and Testing Services Market, by Geography, 2011 - 2018 ($Million) ............................108
29
Global Biomarkers Market, by Application, 2011 - 2018 ($Million)..............................................................................112
30
Global Biomarkers Application Market, by Geography, 2011 - 2018 ($Million) ...........................................................113
31
Global Biomarkers Drug Discovery & Development Process Market, by Geography, 2011 - 2018 ($Million) ............115
32
Global Biomarkers Molecular Diagnostics Market, by Geography, 2011 - 2018 ($Million) .........................................117
33
Global Personalized Medicine (PM) Using Biomarkers in Current Drug Labels .........................................................119
34
Global Biomarkers Personalized Medicine Market, by Geography, 2013 - 2018 ($Million)........................................120
35
Global Biomarker Other Applications Market, by Geography, 2011 - 2018 ($Million).................................................121
36
Global Biomarkers Disease Indication Market, by Type, 2011 - 2013 ($Million).........................................................124
www.marketsandmarkets.com sales@marketsandmarkets.com
11
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
List of Tables Table Titles
..........................................................................................................................Page No
37
Global Biomarkers Disease Indication Market, by Geography, 2011 - 2018 ($Million)...............................................125
38
Increasing Incidence Count for Top 10 Types of Cancer in the U.S. ..........................................................................126
39
Oncology Biomarkers Market, by Geography, 2011 - 2018 ($Million) ........................................................................128
40
Cardiology Biomarkers Market, by Geography, 2011 - 2018 ($Million) ......................................................................132
41
Commonly Used Cardiac Biomarker Tests .................................................................................................................134
42
Biomarker Tests Used for Prognosis ..........................................................................................................................135
43
Neurology Biomarkers Market, by Geography, 2011 - 2018 ($Million) .......................................................................136
44
Other Indication Biomarkers Market, by Geography, 2011 - 2018 ($Million) ..............................................................140
45
Global Biomarkers Market, by Geography, 2011 - 2018 ($Million) .............................................................................143
46
North America: Biomarkers Market, by Discovery Technology, 2011 - 2018 ($Million)...............................................145
47
North America: Biomarkers Market, by Omics Technology, 2011 - 2018 ($Million) ....................................................146
48
North America: Biomarkers Market, by Imaging Technology, 2011 - 2018 ($Million)..................................................147
49
North America: Biomarkers Market, by Bioinformatics Application, 2011 - 2018 ($Million) ........................................148
50
North America: Biomarkers Market, by Services, 2011 - 2018 ($Million)....................................................................149
51
North America: Biomarkers Market, by Application, 2011 - 2018 ($Million) ................................................................150
52
North America: Biomarkers Market, by Disease Indication, 2011 - 2018 ($Million) ....................................................151
53
Europe: Biomarkers Market, by Discovery Technology, 2011 - 2018 ($Million)..........................................................154
54
Europe: Biomarkers Market, by Omics Technology, 2011 - 2018 ($Million) ...............................................................155
55
Europe: Biomarkers Market, by Imaging Technology, 2011 - 2018 ($Million).............................................................156
56
Europe: Biomarkers Market, by Bioinformatics Application, 2011 - 2018 ($Million)....................................................157
57
Europe: Biomarkers Market, by Services, 2011 - 2018 ($Million)...............................................................................158
58
Europe: Biomarkers Market, by Application, 2011 - 2018 ($Million) ...........................................................................159
59
Europe: Biomarkers Market, by Disease Indication, 2011 - 2018 ($Million) ...............................................................160
60
Asia-Pacific: Biomarkers Market, by Discovery Technology, 2011 - 2018 ($Million)...................................................163
61
Asia-Pacific: Biomarkers Market, by Omics Technology, 2011 - 2018 ($Million) ........................................................164
62
Asia-Pacific: Biomarkers Market, by Imaging Technology, 2011 - 2018 ($Million)......................................................165
63
Asia-Pacific: Biomarkers Market, by Bioinformatics Application, 2011 - 2018 ($Million) ............................................166
64
Asia-Pacific: Biomarkers Market, by Services, 2011 - 2018 ($Million)........................................................................167
65
Asia-Pacific: Biomarkers Market, by Application, 2011 - 2018 ($Million) ....................................................................167
66
Asia-Pacific: Biomarkers Market, by Disease Indication, 2011 - 2018 ($Million) ........................................................168
67
RoW: Biomarkers Market, by Discovery Technology, 2011 - 2018 ($Million)..............................................................169
68
RoW: Biomarkers Market, by Omics Technology, 2011 - 2018 ($Million) ...................................................................170
69
RoW: Biomarkers Market, by Imaging Technology, 2011 - 2018 ($Million).................................................................171
70
RoW: Biomarkers Market, by Bioinformatics Application, 2011 - 2018 ($Million) .......................................................172
71
RoW: Biomarkers Market, by Services, 2011 - 2018 ($Million) ..................................................................................173
72
RoW: Biomarkers Market, by Application, 2011 - 2018 ($Million)...............................................................................173
www.marketsandmarkets.com sales@marketsandmarkets.com
12
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
List of Tables Table Titles
..........................................................................................................................Page No
73
RoW: Biomarkers Market, by Disease Indication, 2011 - 2018 ($Million)...................................................................174
74
Agreements, Partnerships, Collaborations, and Joint Ventures, 2011 - 2013 ............................................................177
75
New Product Launch, 2011 - 2013 .............................................................................................................................195
76
Mergers and Acquisitions, 2011 - 2013.......................................................................................................................200
77
Other Developments, 2011 - 2013..............................................................................................................................204
78
Abbott Laboratories: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ......................................................211
79
Abbott Laboratories: Total Revenue, by Segment, 2010 - 2012 ($Million)..................................................................211
80
Abbott Laboratories: Total Revenue, by Geography, 2010 - 2012 ($Million) ..............................................................212
81
Affymetrix, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)..............................................................217
82
Affymetrix, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) .........................................................................217
83
Affymetrix, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million)......................................................................218
84
Agilent Technologies, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million).............................................223
85
Agilent Technologies, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) ........................................................223
86
Agilent Technologies, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million).....................................................224
87
Bio-Rad Laboratories, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)............................................229
88
Bio-Rad Laboratories, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) .......................................................229
89
Bio-Rad Laboratories, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million)....................................................230
90
Eisai Co. Ltd.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ................................................................235
91
Eisai Co. Ltd.: Total Revenue, by Segment, 2010 - 2012 ($Million) ...........................................................................235
92
Eisai Co. Ltd.: Total Revenue, by Geography, 2010 - 2012 ($Million) ........................................................................236
93
Eli Lilly and Company: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ...................................................243
94
Eli Lilly and Company: Total Revenue, by Segment, 2010 - 2012 ($Million) ..............................................................243
95
Eli Lilly and Company: Revenue, by Geography, 2010 - 2012 ($Million)....................................................................244
96
Epigenomics Ag: Total Revenue, 2010 - 2012 ($Million) ............................................................................................247
97
Epigenomics Ag: Total Revenue, by Geography, 2010 - 2012 ($Million)....................................................................248
98
GE Works: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) .....................................................................253
99
GE Works: Total Revenue, by Segment, 2010 - 2012 ($Million) ................................................................................253
100
GE Works: Total Revenue, by Geography, 2010 - 2012 ($Billion)..............................................................................254
101
Genomic Health, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ....................................................258
102
Genomic Health, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million) ............................................................259
103
Glaxosmithkline Plc: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ......................................................262
104
Glaxosmithkline Plc: Total Revenue, by Segment, 2010 - 2012 ($Million) .................................................................262
105
Glaxosmithkline Plc: Revenue for Pharmaceutical Segment, by Geography, 2010 - 2012 ($Million) ........................263
106
Hologic, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)..................................................................267
107
Hologic, Inc.: Total Revenue, by Segments, 2010 - 2012 ($Million) ...........................................................................267
108
Hologic, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million)..........................................................................268
www.marketsandmarkets.com sales@marketsandmarkets.com
13
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
List of Tables Table Titles
..........................................................................................................................Page No
109
Immunomedics, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Millions)....................................................272
110
Immunomedics, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Millions)............................................................272
111
Johnson & Johnson: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ......................................................276
112
Johnson & Johnson: Total Revenue, by Segments, 2010 - 2012 ($Million) ..............................................................276
113
Johnson & Johnson: Medical Devices & Diagnostics Segment Revenue, 2010 - 2012 ($Million) .............................277
114
Johnson & Johnson: Total Revenue, by Geography, 2010 - 2012 ($Million) ..............................................................278
115
Merck & Co: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)...................................................................283
116
Merck & Co: Total Revenue, by Segments, 2010 - 2012 ($Million) ............................................................................283
117
Merck & Co: Total Revenue, by Geography, 2010 - 2012 ($Million)...........................................................................284
118
Myriad Genetics, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)....................................................288
119
Myriad Genetics, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) ...............................................................289
120
Qiagen N.V: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) ...................................................................296
121
Qiagen N.V.: Total Revenue, by Segments, 2010 - 2012 ($Million)............................................................................296
122
Qiagen N.V.: Total Revenue, by Geography, 2010 - 2012 ($Million) ..........................................................................297
123
F. Hoffmann-La Roche Ltd.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)...........................................303
124
F. Hoffmann-La Roche Ltd.: Total Revenue, by Segment, 2010 - 2012 ($Million)......................................................303
125
F. Hoffmann-La Roche Ltd.: Total Revenue, by Geography, 2010 - 2012 ($Million)...................................................304
126
Siemens Ag: Total Revenue and R&D Expenses, 2010 - 2012 ($Million)...................................................................311
127
Siemens Ag: Total Revenue, by Segments, 2010 - 2012 ($Million) ............................................................................311
128
Siemens Ag: Revenue, by Geography, 2010 - 2012 ($Million) ...................................................................................312
129
Thermo Fisher Scientific, Inc.: Total Revenue and R&D Expenses, 2010 - 2012 ($Million) .......................................319
130
Thermo Fisher Scientific, Inc.: Total Revenue, by Segment, 2010 - 2012 ($Million) ..................................................319
131
Thermo Fisher Scientific, Inc.: Total Revenue, by Geography, 2010 - 2012 ($Million) ...............................................320
www.marketsandmarkets.com sales@marketsandmarkets.com
14
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
List of Figures Figure Titles
..........................................................................................................................Page No
1
Biomarker Discovery & Development Process .............................................................................................................34
2
Global Biomarkers Market, by Segments, 2013 ...........................................................................................................35
3
Global Biomarkers Market, by Geography, 2013..........................................................................................................36
4
Life Cycle of A Biomarker .............................................................................................................................................42
5
Biomarkers Market Segmentation ................................................................................................................................43
6
Biomarkers Market Dynamics.......................................................................................................................................44
7
Biomarker Discovery Process ......................................................................................................................................54
8
Biomarkers Market, by Discovery Technologies, 2013 Vs. 2018..................................................................................55
9
Omics Technologies & The Central Dogma..................................................................................................................58
10
Biomarker Discovery Market, by Omics Technologies, 2013 Vs. 2018 ........................................................................59
11
The Central Role of Mass Spectrometry In Proteomics ...............................................................................................63
12
Biomarker Discovery Using 2-D DIGE & MS ................................................................................................................65
13
Transcriptomics Biomarker Discovery ..........................................................................................................................70
14
Biomarker Discovery Market, by Imaging Technologies, 2013 Vs.2018.......................................................................77
15
Biomarker Discovery Market, by Bioinformatics Applications, 2013 Vs.2018...............................................................87
16
Cluster Analysis of Omics Data For Biomarker Discovery............................................................................................90
17
Flow of Clinical Biomarker Services ...........................................................................................................................100
18
Biomarker Services Market, 2013 Vs. 2018 ...............................................................................................................101
19
Biomarkers Market, by Applications, 2013 Vs. 2018...................................................................................................111
20
Drug Discovery & Development Process....................................................................................................................114
21
Biomarkers Market, by Disease Indication, 2013 Vs. 2018 ........................................................................................123
22
Global Biomarkers Market, by Geography, 2013 Vs. 2018.........................................................................................142
23
Key Growth Strategies, 2011 - 2013...........................................................................................................................175
www.marketsandmarkets.com sales@marketsandmarkets.com
15
BT 2120 2013
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
Sample Tables
s e l b a T e l p
Global Biomarker Market, By Discovery Technology, 2011 – 2018 ($Million) Discovery Technology
2010
Omics Technologies Imaging Technologies Bioinformatics Total
2011
2012
2017
CAGR% (2012-2017)
m a S
s e l b
Global Biomarker Discovery Market, By Omics Technology, 2011 – 2018 ($Million) Omics Technologies
2010
Genomics
Metabolomics Total
2012
a T ple
Proteomics
Transcriptomics
2011
2017
CAGR% (2012-2017)
m a S
Global Biomarker discovery Market, By Imaging Technology, 2011 – 2018 ($Million) Imaging Technology
s e l b a T e l p
2010
MRI PET CT SPECT Ultrasound Total
www.marketsandmarkets.com sales@marketsandmarkets.com
2011
m a S
16
2012
2017
CAGR% (2012-2017)
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
Disclaimer MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customers' internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets' research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com
Copyright Š 2013 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
www.marketsandmarkets.com sales@marketsandmarkets.com
17
Biomarkers Market – Global Trends & Forecasts (2013 – 2018)
BT 2120 2013
About MarketsandMarkets We publish about 120 reports a year across 10 main industries. The reports are exhaustive, detailing about 50 micro markets and product segments, and featuring about 80 to 100 market data summary tables, 50 short company profiles, a five-level market breakdown, overviews of more than 300 patents, as well as analyses of the strategic and competitive landscape.
Our clients value our reports especially for the market insight we provide along with the market numbers. Our teams of specialized market analysts and domain experts work within a structured research process to deliver well-analyzed market reports to Fortune 1000 companies globally.
Click here to learn more about us
Related Reports In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [ Te c h n i q u e ( I m m u n o a s s a y, C l i n i c a l C h e m i s t r y, M o l e c u l a r D i a g n o s t i c s , Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017 The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. The U.S. represented the biggest market for IVD equipments accounting for about a half of the total market. The report studies various segments of the IVD market including Clinical Chemistry, Molecular diagnostics, Immunoassays, Hematology and Microbiology.
Report Code: PH 2087
Proteomics Market (Protein Microarray, Mass S p e c t r o m e t r y, N M R S p e c t r o s c o p y, Chromatography, Electrophoresis, Surface Plasmon Resonance, X-ray Crystallography) Instruments, Reagents & Services - Trends & Global Forecasts to 2017 Proteomics, over the last decade, has gained importance in the field of diagnosis and drug research and development. It has various applications, ranging from identifying proteins and performing a protein expression profile by identifying the protein in a specific state of an organism to analyzing the interaction of proteins in living organisms. It also helps to map the modifications of proteins. Thus, it is evolving into an important tool in the field of life sciences.
Report Code: BT 1192
www.marketsandmarkets.com sales@marketsandmarkets.com
18